Webinar: Utilizing Label-Free Real-Time Cell Analysis Technology for Cancer Immunotherapy Applications

free Webinar, Wednesday, November 04, 2015, 17:00

Utilizing Label-Free Real-Time Cell Analysis Technology for Cancer Immunotherapy Applications

T cells can be genetically engineered to express modified TCRs or chimeric antigen receptors (CARs). These approaches overcome the limitations associated with immune tolerance, generate T cells that efficiently target tumors without the need for de novo T cell activation, and have yielded convincing clinical data in recent years. Though traditional end-point assays can be used to evaluate the efficacy of T cell killing in vitro, an assay providing long-term killing-kinetics reminiscent of the “serial killing” nature of T-cells in vivo has remained elusive.

During this webinar, Dr. Abassi will demonstrate the advantages of utilizing the label-free real-time cell analysis (RTCA) technology as an automated homogeneous screening platform to evaluate immune cell killing in vitro. Additional topics will include:

  • Overview of cancer immunotherapies
  • The xCELLigence Real-Time Cell Analysis (RTCA) assay principle 
  • Case Studies: Applications of RTCA in monitoring immune mediated tumor cell killing, e.g., NK cells, cytolytic T cells, ADCC and CAR-T

 

Featured Speaker
Yama A. Abassi, Ph.D.
Vice President of ACEA Biosciences, Inc.
Dr. Yama A. Abassi is Vice President of ACEA Biosciences. He received his undergraduate degree in biochemistry with honors from the State University of New York/Stony Brook in 1992, and a PhD in Molecular, Cell, and Developmental Biology from the University of California at Santa Barbara in 1999. Dr. Abassi joined the Burnham Institute for Cancer Research as an NIH post-doctoral fellow in 1999 and spent the next few years studying oncogene signaling pathways and their role in cancer biology. Dr. Abassi joined ACEA Biosciences in 2003 to help develop a new technology for studying cells using microelectronics. Dr. Abassi’s efforts in this field have earned him numerous publications and patents and have led to the successful development and commercialization of the xCELLigence Real-Time Cell Analysis (RTCA) instrument globally. Dr. Abassi continues to pursue his research interests in developing technologies and applications for in vitro cell-based assays in different fields, including cancer immunotherapy. He also oversees several collaborations with the US EPA that focus on assessing the impact of toxic environmental compounds (in particular, compounds which may interfere with estrogen signaling pathways).

To register, visit: aceabio.webex.com

Download a Flyer: Webinar Cancer Immunotherapy

Find out more about monitoring of immune mediated tumor cell killing: ols-bio.de/car-t

 
 

Passende Artikel

xCELLigence SP

Space saving 96-well Single-Plate System xCelligence SP: Single plate system for 96-well E-Plates. Small foot print, minimum space consumption inside the incubator. Run your Real Time Cell Analysis (RTCA) fully automated and label-free to produce data of highest quality and integrity. A broad application range and full kinetic data recorded make this technology far superior to any conventional assays. Get a wealth of information on the...

Preis auf Anfrage

2801000

xCELLigence MP

The highly flexible System for High Throughput and/or Multi User Applications xCELLigence MP: Multi-Plate system for 6 x 96-well E-Plates. Highest flexibility for labs with really high sample throughput, or simultaneous use by several different users. Run your Real Time Cell Analysis (RTCA) fully automated and label-free to produce data of highest quality and integrity. The software covers a broad application range and incorporates a very...

Preis auf Anfrage

2801003

 
 

Kommentar schreiben

 

Die mit einem * markierten Felder sind Pflichtfelder.